No Data
No Data
Chardan Adjusts PT on Solid Biosciences to $15 From $6, Updates Thesis Ahead of Data Release for Gene Therapy Candidate SGT-003; Maintains Buy Rating
Express News | Solid Biosciences Inc : Chardan Capital Markets Raises Target Price to $15 From $6
Chardan Capital Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Buy Rating Justified for Solid Biosciences Amid Promising Gene Therapy Advances
Express News | Solid Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results
Solid Biosciences Is Maintained at Overweight by Barclays